Immunocore Spon Ads Each Rep One Ord Shs (IMCR) Stock
UK biotech firm developing cancer immune treatments. Here's the price, business snapshot, and what's worth knowing about Immunocore Spon Ads Each Rep One Ord Shs in October 2026.
Immunocore Holdings plc (IMCR) is a UK‑based biotechnology company focused on T‑cell receptor (TCR)‑based immunotherapies for cancer and other serious diseases. The firm is best known for developing bispecific TCR therapies that redirect a patient’s T cells to recognise and attack tumour cells. Its market capitalisation sits around $1.72 billion, reflecting a mix of commercial progress and ongoing clinical development. For investors, key things to watch are regulatory milestones, clinical trial readouts, commercial uptake of approved therapies and partnership or licensing deals that can influence revenue and R&D funding. As a clinical-stage biopharmaceutical company, Immunocore can offer upside linked to successful trials but also carries higher volatility and binary risks — trials may fail, timelines can slip and drug adoption can vary. This summary is for general, educational purposes only and not personal financial advice; suitability depends on individual circumstances and risk tolerance.
Immunocore Spon Ads Each Rep One Ord Shs (IMCR) Stock Forecast
Analyst price target, next 12 months
$63.44
+113.5% vs today's $29.71
Price range over the last 12 months
Close to its 12-month low
Analysts covering Immunocore Spon Ads Each Rep One Ord Shs have a consensus 12-month target of $63.44, above the current price of $29.71.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immunocore's stock with a target price of $63.44, indicating strong growth potential.
Financial Health
Immunocore is performing well with strong revenue, high cash flow, and impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
TCR Immunotherapy Focus
Immunocore’s unique T‑cell receptor approach aims to broaden immune targeting of tumours, though clinical results and uptake can vary.
Clinical Milestones Matter
Trial readouts and regulatory decisions tend to move the share price significantly, offering potential upside alongside binary risk.
Commercial & Partnership Drivers
Revenue and scale depend on market adoption and collaborations; partnerships can de‑risk development but outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
